Provided by Tiger Trade Technology Pte. Ltd.

Relay Therapeutics

8.86
-0.2400-2.64%
Post-market: 8.85-0.0100-0.11%16:33 EST
Volume:1.09M
Turnover:9.67M
Market Cap:1.54B
PE:-5.06
High:9.00
Open:8.97
Low:8.69
Close:9.10
52wk High:9.54
52wk Low:1.78
Shares:173.32M
Float Shares:102.63M
Volume Ratio:0.56
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7494
EPS(LYR):-2.3638
ROE:-41.14%
ROA:-25.37%
PB:2.53
PE(LYR):-3.75

Loading ...

Why Relay Therapeutics (RLAY) Is Up 9.4% After FDA Breakthrough Tag For Breast Cancer Combo

Simply Wall St.
·
Feb 09

BRIEF-Relay Therapeutics Announces Zovegalisib Granted Therapy Designation By FDA For Pik3ca-Mutant

Reuters
·
Feb 03

Relay Therapeutics announces U.S. FDA granted BTD to zovegalisib

TIPRANKS
·
Feb 03

Relay Therapeutics Wins FDA Breakthrough Therapy Designation for Zovegalisib in Advanced Breast Cancer

Reuters
·
Feb 03

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for Pik3CA-Mutant, Hr+/Her2- Advanced Breast Cancer

THOMSON REUTERS
·
Feb 03

What Relay Therapeutics (RLAY)'s Zovegalisib Data and Insider Sales Mean For Shareholders

Simply Wall St.
·
Feb 02

Top Relay Therapeutics Insiders Quietly Cash Out in Coordinated Stock Moves

TIPRANKS
·
Jan 30

Relay Therapeutics : Oppenheimer Raises to Outperform From Perform

THOMSON REUTERS
·
Jan 26

Relay Therapeutics Raised to Outperform From Perform by Oppenheimer

Dow Jones
·
Jan 26

Oppenheimer Upgrades Relay Therapeutics to Outperform From Market Perform, Price Target is $14

MT Newswires Live
·
Jan 26

Relay Therapeutics (RLAY): Valuation Check After Encouraging New Zovegalisib Breast Cancer Data

Simply Wall St.
·
Dec 26, 2025

ADVISORY-Alert from Equity-Insider.com was published in error and has been withdrawn

Reuters
·
Dec 17, 2025

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

THOMSON REUTERS
·
Dec 17, 2025

Will Early Zovegalisib Data in HR+/HER2- Breast Cancer Change Relay Therapeutics' (RLAY) Narrative?

Simply Wall St.
·
Dec 14, 2025

Relay Therapeutics Raised to Overweight From Equal-Weight by Wells Fargo

Dow Jones
·
Dec 13, 2025

Sector Update: Health Care Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Dec 12, 2025

Relay Therapeutics Reports 'Robust Activity' in Study of Zovegalisib to Treat Breast Cancer

MT Newswires Live
·
Dec 12, 2025

Relay Therapeutics Reports Promising Zovegalisib Results in Phase 3 Breast Cancer Trial

Reuters
·
Dec 12, 2025

Barclays Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

TIPRANKS
·
Nov 24, 2025

Relay Therapeutics (RLAY): A Fresh Board and Narrower Losses—What Does It Mean for Valuation?

Simply Wall St.
·
Nov 17, 2025